[1]徐 凤,黄金灿,马右维,等.白蛋白-胆红素评分对远端胆管癌病人术后预后的评估价值[J].肠外与肠内营养杂志,2024,(06):359-363.[doi:10.16151/j.1007-810x.2024.06.007]
　XU Feng,HUANG Jin-can,MA You-wei,et al.The predictive value of the ALBI score for the postoperative prognosis of distal cholangiocarcinoma after radical surgery[J].PARENTERAL & ENTERAL NUTRITION,2024,(06):359-363.[doi:10.16151/j.1007-810x.2024.06.007]
点击复制

白蛋白-胆红素评分对远端胆管癌病人术后预后的评估价值()
分享到：

《肠外与肠内营养》杂志[ISSN:1007-810X/CN:32-1477/R]

卷:
期数:
2024年06期
页码:
359-363
栏目:
论著
出版日期:
2024-12-10

文章信息/Info

Title:
The predictive value of the ALBI score for the postoperative prognosis of distal cholangiocarcinoma after radical surgery
作者:
徐 凤 1; 黄金灿 2; 马右维2; 吕少诚 2; 姜 涛2
1.北京城市学院生物医药学部，北京 100083；2.首都医科大学附属北京朝阳医院肝胆外科，北京 100020
Author(s):
XU Feng1;  HUANG Jin-can2;  MA You-wei2;  L? Shao-cheng2;  JIANG Tao2
1. School of Biomedicine, Beijing City University, Beijing 100083, China；2. Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Beijing 100020, China
关键词:
胆管肿瘤 ; 远端胆管癌 ; 营养评估 ; 预后
Keywords:
Bile duct cancer;  Distal cholangiocarcinoma;  Nutrition evaluation;  Prognosis
分类号:
R735.8
DOI:
10.16151/j.1007-810x.2024.06.007
文献标志码:
A
摘要:
目的：探讨白蛋白-胆红素（ALBI）评分对远端胆管癌病人术后预后的评估价值。 方法：回顾性分析2014年1月至2022年12月首都医科大学附属北京朝阳医院肝胆外科收治的行手术治疗的156例远端胆管癌病人临床资料。根据术前血清白蛋白和总胆红素计数,计算ALBI评分，以ALBI评分最佳截断值为截止点，将病人分为低ALBI组和高ALBI组，分析比较不同分组病人的远期预后情况，并进一步通过单因素及多因素分析筛选影响病人远期预后的危险因素。 结果：以ALBI最佳截断值为截止点，将病人分为低ALBI组（ALBI ≤ -1.67，92例）和高ALBI （ALBI > -1.67，64例）。低ALBI组和高ALBI组病人中位生存时间分别为33个月和20个月，病人术后1年、3、5年的总体生存率分别为85.4%、43.8%、35.8%和65.5%、23.4%、13.6%（χ2 = 8.882，P = 0.003）。单因素及多因素分析结果提示，高ALBI、CA19-9 > 37 U/mL和淋巴结转移是影响术后远期生存的独立危险因素。 结论：术前ALBI评分可以作为预测远端胆管癌病人远期生存的有效指标。
Abstract:
Objective: To evaluate the prognostic value of albumin-bilirubin (ALBI) score in patients with distal cholangiocarcinoma (dCCA) after radical surgery. Methods: This retrospective study analyzed clinical data from 156 patients diagnosed with distal cholangiocarcinoma who underwent surgical treatment at the Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, affiliated with Capital Medical University, between January 2014 and December 2022. All patients gave informed consent and medical ethics guidelines were followed. The Albumin-Bilirubin (ALBI) score was calculated based on preoperative serum albumin and total bilirubin levels. Patients were then stratified into low ALBI and high ALBI groups using the optimal cut-off value. The study aimed to assess and compare the long-term prognosis of patients in these groups and to identify risk factors that influence their long-term prognosis using univariate and multivariate analyses. Results: Using the optimal ALBI cut-off value, patients were stratified into a low ALBI group (ALBI ≤ -1.67, 92 cases) and a high ALBI group (ALBI > -1.67, 64 cases). The median survival time for patientsin the low ALBI group was 33 months, while the median survival time for patients in the high ALBI group was 20 months. The overall survival rates at 1 year, 3 years, and 5 years postoperatively were 85.4%, 43.8%, and 35.8% for the low ALBI group, and 65.5%, 23.4%, and 13.6% for the high ALBI group, respectively (χ2 = 8.882, P = 0.003). Results from both univariate and multivariate analyses indicated that high ALBI, CA19-9 > 37U/ml and lymph node metastasis were independent risk factors of long-term postoperative survival. Conclusion: In patients with distal cholangiocarcinoma, the preoperative ALBI score may be an effective indicator for predicting long-term survival.

参考文献/References:


[1] Ilyas SI, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma[J]. Gastroenterology, 2013, 145(6): 1215-1229.
[2] Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors[J]. Ann Surg, 1996, 224(4): 463-473.
[3] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors[J]. Liver Int, 2019, 39(Suppl 1):19-31.
[4] Zhou YM, Liu SC, Wu LP, et al. Survival after surgical resection of distal cholangiocarcinoma: a systematic review and metaanalysis of prognostic factors[J]. Asian J Surg, 2017, 40(2):129-138.
[5] Strijker M, Belkouz A, van der Geest LG, et al. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study[J]. Acta Oncol, 2019, 58(7): 1048-1055.
[6] 张长坤, 张龙辉, 王 东, 等. 术前肝功能Child-Pugh评分与白蛋白-胆红素评分对肝癌患者肝切除术后肝衰竭和预后的预测价值[J]. 中华消化外科杂志, 2018, 17(5): 474-482.
[7] Matsukane R, Watanabe H, Hata K, et al. Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy[J]. Sci Rep, 2021, 11(1): 15057.
[8] Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6): 550-558.
[9] 杨林华, 刘颖斌. 梗阻性黄疸围手术期营养支持策略[J]. 肠外与肠内营养, 2020, 27(5): 257-260.
[10] Luvira V, Satitkarnmanee E, Pugkhem A, et al. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma[J]. Cochrane Database Syst Rev, 2021, 9(9): CD012814.
[11] Dickson PV, Behrman SW. Distal cholangiocarcinoma[J]. Surg Clin North Am, 2014, 94(2): 325-342.
[12] DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution[J]. Ann Surg, 2007, 245(5):755-762.
[13] Ethun CG, Le N, Lopez-Aguiar AG, et al. Pathologic and prognostic implications of incidental versus nonincidental gallbladder cancer: a 10-institution study from the United States extrahepatic biliary malignancy consortium[J]. Am Surg, 2017, 83(7): 679-686.
[14] Kim HJ, Kim CY, Hur YH, et al. The prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lymphovascular invasion[J]. Surg Today, 2014, 44(10): 1879-1886.
[15] Terasaki F, Sugiura T, Okamura Y, et al. Use of preoperative controlling nutritional status (CONUT) score as a better prognostic marker for distal cholangiocarcinoma after pancreatoduodenectomy[J]. Surg Today, 2021, 51(3): 358-365.
[16] 刘 锐, 陈伟伟, 黄 坤, 等. MNA-SF和NRS 2002评估老年恶性梗阻性黄疸病人营养状况及其影响因素的应用研究[J]. 肠外与肠内营养, 2019, 26(2): 74-78.
[17] Zhang ZQ, Xiong L, Zhou JJ, et al. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC[J]. World J Surg Oncol, 2018, 16(1): 208.
[18] Mao SQ, Yu X, Shan YY, et al. Albumin-Bilirubin (ALBI) and monocyte to lymphocyte ratio(MLR)-based nomogram model to predict tumor recurrence of AFP-negative hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 1355-1365.
[19] Kudo M. Newly developed modified ALBI grade shows better prognostic and predictive value for hepatocellular carcinoma[J]. Liver Cancer, 2022, 11(1): 1-8.
[20] Wang YY, Zhong JH, Su ZY, et al. Albumin-bilirubin versus childpugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J]. Br J Surg, 2016, 103(6): 725-734.
[21] Wu N, Chen G, Hu HL, et al. Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas[J]. Nutr Cancer, 2015, 67(3): 481-485.
[22] O?ate-Oca?a LF, Aiello-Crocifoglio V, Gallardo-Rincón D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma[J]. Ann Surg Oncol, 2007, 14(2): 381-389.
[23] Peters SJAC, Vanhaecke T, Papeleu P, et al. Co-culture of primary rat hepatocytes with rat liver epithelial cells enhances interleukin-6-induced acute-phase protein response[J]. Cell Tissue Res, 2010,340(3): 451-457.
[24] Honda H, Qureshi AR, Heimbürger O, et al. Serum albumin, Creactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD[J]. Am J Kidney Dis, 2006, 47(1): 139-148.
[25] Shen JY, Wen TF, Li C, et al. The prognostic prediction role of preoperative serum albumin level in patients with intahepatic cholangiocarcinoma following hepatectomy[J]. Dig Dis, 2018, 36(4): 306-313.
[26] Waghray A, Sobotka A, Marrero CR, et al. Serum albumin predicts survival in patients with hilar cholangiocarcinoma[J].Gastroenterol Rep (Oxf), 2017, 5(1): 62-66.
[27] Nagino M, Takada T, Miyazaki M, et al. Preoperative biliary drainage for biliary tract and ampullary carcinomas[J]. J Hepatobiliary Pancreat Surg, 2008, 15(1): 25-30.
[28] Abdel Wahab M, Fathy O, Elghwalby N, et al. Resectability and prognostic factors after resection of hilar cholangiocarcinoma[J].Hepatogastroenterology, 2006, 53(67): 5-10.
[29] Belghiti J, Ogata S. Preoperative optimization of the liver for resection in patients with hilar cholangiocarcinoma[J]. HPB(Oxford), 2005, 7(4): 252-253.
[30] 王思珍, 王新波. 胆道引流对梗阻性黄疸肠黏膜屏障的调节作用[J]. 肠外与肠内营养, 2012, 19(3): 184-187.
[31] Xu S, Zhang XP, Zhao GD, et al. Development and validation of an online calculator to predict early recurrence and long-term survival in patients with distal cholangiocarcinoma afterpancreaticoduodenectomy[J]. J Hepatobiliary Pancreat Sci, 2022,29(11): 1214-1225.

备注/Memo

备注/Memo:
作者简介 ：徐 凤，副主任护师，从事主要研究方向为外科护理管理与实践、护理教育研究。E-mail：BCU_XuF@126.com
更新日期/Last Update: 1900-01-01